Amneal Pharmaceuticals, Inc. announced it has received Abbreviated New Drug Application (?ANDA?) approval from the U.S. Food and Drug Administration (?FDA?) for ciprofloxacin and dexamethasone otic suspension. This product is a combination of ciprofloxacin, a fluoroquinolone antibacterial and dexamethasone, a corticosteroid, and is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.94 USD | +1.19% | +10.61% | -2.14% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.14% | 1.81B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals, Inc Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension